# US 2026/0092090 A1 · Production of nerve growth factor (ngf) and of muteins thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092090 A1
- Document ID: US20260092090A1
- Status: Published application
- Kind: A1
- Application number: 19/265,384
- Filed: 2025-07-10
- Published: 2026-04-02
- Earliest claimed: 2018-04-27
- Assignees: Chiesi Farmaceutici S.p.A.
- Applicants: Chiesi Farmaceutici SpA
- Inventors: Bruno Pietro Imbimbo
- Web page: https://patentgrep.com/patent/US20260092090A1

## CPC

- C07K 14/48: Nerve growth factor [NGF]
- C07K 1/165: {mixed-mode chromatography}
- C12N 9/6427: {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a process for production of nerve growth factor (NGF) and muteins thereof, in particular muteins of human NGF. The process of the present invention yields nerve growth factor (NGF) and muteins thereof, e.g. from recombinant sources, at high purity. Aspects related to the process of the present invention, such as muteins obtainable thereby, are also described. The respective muteins may be characterized e.g. by improved detectability and/or reduced nociceptive activity, compared to wildtype human NGF.

## Claims

### Claim 1

A process for production of a mutein of nerve growth factor (NGF), wherein the mutein is characterized by more than 90% sequence identity with wild type human NGF (SEQ ID NO: 2),
under the proviso that the mutein is characterized by at least one mutation, preferably amino acid substitution, at any of positions 95-101 of SEQ ID NO: 2,
comprising the following steps:
(a) obtaining a precursor of NGF or of the mutein thereof,
(d) purification,
wherein the purification comprises purification on a mixed mode stationary phase.

### Claim 2 (depends on 1)

The process according to claim 1, wherein the mutein is characterized by substitution of arginine in position 100, preferably wherein arginine at position 100 is substituted by glutamic acid.

### Claim 3 (depends on 1)

The process according to claim 1, wherein the precursor of NGF or a mutein thereof is subjected to a step
(c) exposure to a protease prior to step (d).

### Claim 4 (depends on 3)

The process according to claim 3, wherein no chromatographic purification of NGF or mutein thereof is performed prior to the exposure to protease.

### Claim 5 (depends on 1)

The process according to claim 1, wherein (a) obtaining comprises recombinant expression, preferably in a host cell, preferably E. coli, and more preferably E. coli Rosetta (DE3).

### Claim 6 (depends on 1)

The process according to claim 1, wherein the precursor of NGF or of the mutein thereof is obtained in inclusion bodies.

### Claim 7 (depends on 1)

The process according to claim 1, wherein the process comprises a step
(b) of (re-)folding the NGF or mutein thereof.

### Claim 8 (depends on 3)

The process according to claim 3, wherein the protease is trypsin, preferably porcine trypsin.

### Claim 9 (depends on 1)

The process according to claim 1, wherein (d) purification comprises the following steps, preferably in sequential order:
(d1) capturing,
(d2) polishing
and wherein the capturing is carried out using mixed mode chromatography.

### Claim 10 (depends on 1)

The process according to claim 1, wherein the mixed mode chromatography comprises the use of a stationary phase having a charged group, preferably negatively charged group, and an aromatic group and/or a hydrophobic group.

### Claim 11 (depends on 9)

The process according to claim 9, wherein the polishing is carried out using cation exchange chromatography, preferably a cation exchange stationary phase such as SP sepharose, more preferably SP sepharose HP.

### Claim 12 (depends on 1)

The process according to claim 1, wherein the mutein is characterized by at least the substitution of proline at position 61 of SEQ ID NO: 2 by another amino acid, preferably by serine.

### Claim 13 (depends on 1)

Mutein of NGF obtainable by the process of claim 1.

### Claim 14 (depends on 13)

The mutein of NGF according to claim 13, wherein the mutein is substantially free of impurities.

### Claim 15 (depends on 13)

A composition comprising the mutein according to claim 13, wherein the composition comprises acetate and/or wherein the composition has a pH from 4.5 to 6.5, preferably 5.0 to 6.0.

### Claim 16 (depends on 13)

The mutein of NGF according to claim 13 for use in a method for treatment of the human or animal body by therapy.
